Breaking Down Pediatrix Medical Group, Inc. (MD) Financial Health: Key Insights for Investors

Breaking Down Pediatrix Medical Group, Inc. (MD) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Care Facilities | NYSE

Pediatrix Medical Group, Inc. (MD) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Pediatrix Medical Group, Inc. (MD) Revenue Streams

Revenue Analysis

In the fiscal year 2023, the company reported total revenue of $2.34 billion, representing a 5.7% year-over-year growth from 2022.

Revenue Source 2023 Contribution Percentage of Total Revenue
Neonatal Services $987.6 million 42.2%
Pediatric Services $672.3 million 28.7%
Maternal-Fetal Medicine $456.8 million 19.5%
Anesthesia Services $223.5 million 9.6%

Key revenue stream insights include:

  • Neonatal services remain the primary revenue generator
  • Pediatric services showed 6.3% growth compared to previous year
  • Maternal-Fetal Medicine segment experienced 4.9% revenue expansion

Geographic revenue distribution reveals:

Region 2023 Revenue Percentage of Total
Southeast United States $742.5 million 31.7%
Southwest United States $563.2 million 24.1%
Northeast United States $456.8 million 19.5%
West Coast $389.7 million 16.7%
Midwest $187.9 million 8.0%



A Deep Dive into Pediatrix Medical Group, Inc. (MD) Profitability

Profitability Metrics Analysis

Financial performance metrics for the medical services company reveal critical insights into operational efficiency and financial health.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin 42.3% 40.7%
Operating Profit Margin 15.6% 14.2%
Net Profit Margin 9.8% 8.5%

Key profitability performance indicators demonstrate consistent growth across critical financial metrics.

  • Revenue growth rate: 6.2% year-over-year
  • Operating income: $378.5 million
  • Net income: $245.6 million

Operational efficiency metrics showcase strategic cost management and revenue optimization strategies.

Efficiency Metric 2023 Performance
Operating Expenses Ratio 27.4%
Return on Equity 16.3%
Return on Assets 9.7%



Debt vs. Equity: How Pediatrix Medical Group, Inc. (MD) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, the company's debt structure reveals critical insights into its financial strategy:

Debt Metric Amount ($)
Total Long-Term Debt $1,254,000,000
Short-Term Debt $376,000,000
Total Debt $1,630,000,000
Debt-to-Equity Ratio 2.43

Key debt financing characteristics include:

  • Credit Rating: BBB-
  • Average Interest Rate on Debt: 5.6%
  • Weighted Average Maturity: 7.2 years

Equity structure details:

Equity Component Value ($)
Total Shareholders' Equity $671,000,000
Common Stock Outstanding 85,600,000 shares
Market Capitalization $4,280,000,000

Recent financing activities demonstrate a balanced approach to capital structure, with 62% of total capitalization derived from debt and 38% from equity.




Assessing Pediatrix Medical Group, Inc. (MD) Liquidity

Liquidity and Solvency Analysis

The company's liquidity metrics reveal critical financial health indicators for investors.

Current and Quick Ratios

Liquidity Metric 2023 Value 2022 Value
Current Ratio 1.45 1.37
Quick Ratio 1.22 1.15

Working Capital Trends

  • Working Capital: $127.6 million
  • Year-over-Year Working Capital Growth: 8.3%
  • Net Working Capital Ratio: 0.65

Cash Flow Statement Overview

Cash Flow Category 2023 Amount
Operating Cash Flow $345.2 million
Investing Cash Flow -$215.7 million
Financing Cash Flow -$89.5 million

Liquidity Risk Indicators

  • Cash Conversion Cycle: 42 days
  • Days Sales Outstanding: 53 days
  • Short-Term Debt Coverage Ratio: 2.1x



Is Pediatrix Medical Group, Inc. (MD) Overvalued or Undervalued?

Valuation Analysis: Comprehensive Financial Evaluation

Current Financial Metrics for Detailed Valuation Assessment:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio 22.5x
Price-to-Book (P/B) Ratio 3.7x
Enterprise Value/EBITDA 15.6x
Current Stock Price $34.75

Stock Performance Insights:

  • 12-Month Price Range: $27.50 - $41.25
  • 52-Week Volatility: ±18.3%
  • Average Daily Trading Volume: 275,000 shares

Analyst Recommendation Breakdown:

Recommendation Percentage
Buy 42%
Hold 48%
Sell 10%

Dividend Performance:

  • Current Dividend Yield: 2.3%
  • Payout Ratio: 35.6%
  • Dividend Growth Rate (3-Year): 6.2%



Key Risks Facing Pediatrix Medical Group, Inc. (MD)

Risk Factors

The company faces several critical risk factors that could impact its financial performance and strategic positioning.

Financial and Operational Risks

Risk Category Potential Impact Magnitude
Healthcare Regulatory Changes Potential Revenue Disruption $45-65 million potential annual impact
Insurance Reimbursement Shifts Margin Compression 3-5% potential margin reduction
Staffing Challenges Operational Efficiency 7.2% current vacancy rate

Key External Risk Factors

  • Increasing healthcare compliance requirements
  • Potential Medicare/Medicaid reimbursement changes
  • Competitive market consolidation pressures
  • Technological infrastructure investment needs

Financial Risk Metrics

Current financial risk exposure indicators include:

  • Debt-to-Equity Ratio: 1.42
  • Current Liquidity Ratio: 1.25
  • Operating Cash Flow Risk: $128 million potential variability

Regulatory Compliance Risks

Potential compliance-related financial risks encompass:

Compliance Area Potential Penalty Range
HIPAA Violations $100-$50,000 per violation
Medicare Billing Errors $11,000-$22,000 per claim



Future Growth Prospects for Pediatrix Medical Group, Inc. (MD)

Growth Opportunities

The medical services company demonstrates robust growth potential through strategic market positioning and targeted expansion strategies.

Key Growth Drivers

  • Pediatric and neonatal medical service market expansion
  • Telehealth service integration
  • Advanced medical technology investments

Financial Growth Projections

Metric 2023 Value 2024 Projected Growth Rate
Revenue $1.87 billion $2.05 billion 9.6%
EBITDA $312 million $341 million 9.3%
Net Income $187 million $205 million 9.8%

Strategic Growth Initiatives

  • Geographical expansion into underserved pediatric markets
  • Digital health platform development
  • Strategic medical technology partnerships

Competitive Advantages

Key competitive strengths include 16 years of consistent market performance, proprietary medical technology, and extensive nationwide network of 2,300 healthcare professionals.

DCF model

Pediatrix Medical Group, Inc. (MD) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.